Envirologix, Inc. engages in the development, manufacture, and supply of immunoassay test kits for food production applications. The company was founded by Bruce S. Ferguson in 1996 and is headquartered in Portland, ME.

The Eli and Edythe L. Broad Institute of MIT and Harvard (/ˈbroʊd/), often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and is partners with Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.

New England Biolabs is focused on the discovery and development of recombinant and native enzymes for genomic research. It offers restriction endonucleases for DNA digestion; PCR, polymerases, and amplification technologies for PCR applications; DNA modifying enzymes and cloning technologies; reagents for DNA and RNA sample preparation; DNA, RNA, and protein markers and ladders for electrophoresis applications; reagents for RNA research; and gene expression tools for DNA, RNA, and protein transfection of cell lines. The company also offers cellular analysis solutions; reagents, enzymes, antibodies, and DNA controls for epigenetics research; protein expression and purification technologies; competent cells for transformation and protein expression; protein tools; glycobiology products; and plasmids and DNAs for use in cloning experiments. New England Biolabs was founded in 1974 and is based in Ipswich, Massachusetts.

Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery.

Part of LumiraDX Ltd., LumiraDx UK Ltd. is a British company located in London. The firm develops portable diagnostic instrument and platform for community-based healthcare. It was founded in 2014 by Ronald Zwanziger and Jerome Francis McAleer. Ronald Zwanziger has been the CEO since the company founding. On September 28, 2021 CA Healthcare Acquisition Corp. acquired LumiraDx UK Ltd. for $2,537.21 million.\nThe company says this about itself: LumiraDx is a next-generation point of care diagnostics company that is transforming community-based healthcare. Founded in 2014, the company manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. LumiraDx's diagnostic testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacy, schools, and workplaces to screen, diagnose and monitor wellness as well as disease. The company has on the market and in development 30+ tests covering infectious diseases, cardiovascular disease, diabetes and coagulation disorders, all on the LumiraDx Platform. In addition, the company has a comprehensive portfolio of fast, accurate and cost-efficient COVID-19 testing solutions from the lab to point of need. Based in the UK with more than 1500 employees worldwide, LumiraDx is supported by institutional and strategic investors including the Bill & Melinda Gates Foundation, Morningside Ventures, U.S. Boston Capital Corporation, and Petrichor Healthcare Capital Management.

Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.

Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. It is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the dna.

QIAGEN GmbH provides products for preanalytical sample preparation and molecular diagnostics solutions. It develops and markets consumable products and automated solutions to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. The company was founded in 1984 and is headquartered in Hilden, Germany.

Beijing Academy of Agriculture & Forestry Sciences is a Chinese private company with domestic subsidiaries, that operates as an agricultural research organization.

Affymetrix, Inc. was an American company that manufactured DNA microarrays; it was based in Santa Clara, California, United States. The company was acquired by Thermo Fisher Scientific in March 2016. The company was founded by Stephen Fodor in 1992. It began as a unit in Affymax N.V. in 1991 by Fodor's group, which had in the late 1980s developed methods for fabricating DNA microarrays, called "GeneChip" according to the Affymetrix trademark, using semiconductor manufacturing techniques. The company's first product, an HIV genotyping GeneChip, was introduced in 1994 and the company went public in 1996. As a result of its pioneering work and the ensuing popularity of microarray products, Affymetrix derived significant benefit from its patent portfolio in this area.

Inari is a biotechnology company that aims to transform agriculture and its impact on society and the environment. It embraces diversity in every aspect of its business to drive innovation and help build a new food system. The company's technology matches the complexity of nature using predictive design and multiplex gene editing to unlock the full potential of the seed. Inari's SEEDesign platform is their point of distinction, using unsurpassed technology to enhance any crop for any geography to develop step-change products with a clear go-to-market approach.

Commonwealth Scientific & Industrial Research Organisation provides scientific and industrial research services. It plays a role in collaboration within the Australian national innovation system and as an advisor to government, industry and the community. The company was founded in 1916 and is headquartered in Canberra, Australia.

Sigma Aldrich Co. Ltd. engages in the science and technology company. Its products include analytical standards, gas chromatography, spectroscopy, acids and bases, catalysis and inorganics, organometallics, solvents, antibodies, biochemical and reagents, cell biology, microbiology, and polymer sciences. It also offers basic research, product and process development, manufacturing and production, and regulatory compliance services. The company was founded on December 10, 1987 and is headquartered in Gillingham, the United Kingdom.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

MGI Tech is committed to enabling effective and affordable healthcare solutions for all. MGI produces sequencing devices, equipment, consumables and reagents to support life science research, medicine and healthcare. MGI’s multi-omics platforms include genetic sequencing, mass spectrometry and medical imaging. Providing real-time, comprehensive, life-long solutions, its mission is to advance life science tools and lead digital health innovation.

Rewrite Therapeutics, Inc., a subsidiary of Intellia Therapeutics, Inc., is a company headquartered in Emeryville, CA. The firm operates as a biotechnology company focused on novel DNA writing technologies. It was founded in 2016 by Shakked Halperin and David Schaffer. Shakked Halperin has been the CEO since that date. Rewrite Therapeutics, Inc. was acquired by Intellia Therapeutics, Inc. on February 04, 2022 for $200 million.

Alfresa Pharma Corp. manufactures and distributes pharmaceutical products, diagnostics, medical devices, and pharmaceutical raw materials. The company was founded on December 24, 1939 and is headquartered in Osaka, Japan.

BGI Shenzhen Co., Ltd. engages in the equity investment and asset management. Its business scope includes research and development and sales of computer hardware and software and peripheral equipment technology; import and export of goods and technology; equity investment; investment in industrial development; and aquatic product farming and sales. The company was founded on August 21, 2008 and is headquartered in Shenzhen, China.

Shanghai Berger Medical Technology Co., Ltd., established on 2017-03-01, Business scope includes licensed projects:Production of Class III Medical Devices;Class III medical device business;Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Instrument sales;Health Consulting Services(Does not include medical services);Data processing and storage support services;Conference and Exhibition Services;Auto New Car Sales.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)